Research prototype, not medical advice.

A single infusion of NTLA-2001 (CRISPR editing of the TTR gene in the liver) lowers TTR by about 87% at 0.3 mg/kg (phase 1).

Confidence
Established
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisNTLA-2001 (CRISPR editing of the TTR gene)Transthyretin amyloidosis (ATTR)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore et al. · New England Journal of Medicine 2021
— Verified